Karol Sokolowski
Karol Sokolowski has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Richard A. Gemeinhart
Department of Pharmaceutical Sciences, University of Illinois Chicago, Chicago, IL, USA
2 shared publications - Zackery P. Bulman
Department of Pharmacy Practice University of Illinois Chicago Chicago Illinois USA
2 shared publications - Alan R. Hauser
Department of Microbiology-Immunology, Northwestern University, Feinberg School of Medicine
1 shared publication - Amisha Rana
Department of Pharmacy Practice, University of Illinois at Chicago College of Pharmacy, Chicago, Illinois, USA
1 shared publication - Azure Dominique Grant
People Science, Inc, Los Angeles, CA
1 shared publication - Brett Newswanger
ClostraBio, Inc., Chicago, IL, USA
1 shared publication
Latest Publications
- Open Access
CLB101 TM Improves Gastrointestinal Symptom Burden in Overweight Adults: A Randomized, Double-Blind, Placebo-Controlled Study
Background: Anaerostipes caccae CLB101 TM is a next-generation probiotic that directly produces butyrate and is hypothesized to reduce gastrointestinal symptoms by strengthening intestinal barrier integrity. Clinical evidence for A. caccae in symptomatic adult populations remains limited. Methods: Ninety-three adults were randomized 1:1 to CLB101 TM (n=47) or placebo (n=46) for 28 days. The primary outcome was safety and tolerability as assessed by the number, frequency, and severity of adverse events. Secondary outcomes were focused on exploring signals of efficacy, and included change in the Gastrointestinal Symptom Rating Scale (GSRS) composite score from baseline to Week 4. Five GSRS subcategories were additionally evaluated. Exploratory endpoints included daily self-reported GI symptoms, as well as stool and blood measures of intestinal barrier function. Results: 71 participants were evaluated for the GSRS (77.5% female, aged 42.1 SD 12 years, BMI mean 31.3 SD 3.6). No adverse events were reported in the placebo arm, while three self-limiting adverse events were associated with CLB101 TM administration. CLB101 TM reduced GI symptom burden versus placebo on the primary GSRS composite at Week 4 (mean change: −1.60 vs −0.90; MWU p=0.040). Two secondary subscales reached significance after FDR-BH correction: Reflux (mean change: −1.26 vs −0.30; FDR-adjusted p=0.024) and Abdominal Pain (mean change: −1.86 vs −0.83; FDR-adjusted p=0.024). Daily symptom diaries showed trends toward greater reductions in abdominal discomfort, bloating, and flatulence in the active arm at the end of study. This study population did not demonstrate signs of intestinal barrier dysfunction. Product adherence averaged 97.7%. Conclusions: CLB101 TM was safe and tolerable and significantly improved overall GI symptom burden, reflux, and abdominal pain after four weeks of daily supplementation in overweight symptomatic adults. Trial Registration: The trial was approved by Sterling IRB (14583-NACraft) and registered with ClinicalTrials.gov ( NCT07336615 ).
Open AccessCLB101 TM Improves Gastrointestinal Symptom Burden in Overweight Adults: A Randomized, Double-Blind, Placebo-Controlled Study
Background: Anaerostipes caccae CLB101 TM is a next-generation probiotic that directly produces butyrate and is hypothesized to reduce gastrointestinal symptoms by strengthening intestinal barrier integrity. Clinical evidence for A. caccae in symptomatic adult populations remains limited. Methods: Ninety-three adults were randomized 1:1 to CLB101 TM (n=47) or placebo (n=46) for 28 days. The primary outcome was safety and tolerability as assessed by the number, frequency, and severity of adverse events. Secondary outcomes were focused on exploring signals of efficacy, and included change in the Gastrointestinal Symptom Rating Scale (GSRS) composite score from baseline to Week 4. Five GSRS subcategories were additionally evaluated. Exploratory endpoints included daily self-reported GI symptoms, as well as stool and blood measures of intestinal barrier function. Results: 71 participants were evaluated for the GSRS (77.5% female, aged 42.1 SD 12 years, BMI mean 31.3 SD 3.6). No adverse events were reported in the placebo arm, while three self-limiting adverse events were associated with CLB101 TM administration. CLB101 TM reduced GI symptom burden versus placebo on the primary GSRS composite at Week 4 (mean change: −1.60 vs −0.90; MWU p=0.040). Two secondary subscales reached significance after FDR-BH correction: Reflux (mean change: −1.26 vs −0.30; FDR-adjusted p=0.024) and Abdominal Pain (mean change: −1.86 vs −0.83; FDR-adjusted p=0.024). Daily symptom diaries showed trends toward greater reductions in abdominal discomfort, bloating, and flatulence in the active arm at the end of study. This study population did not demonstrate signs of intestinal barrier dysfunction. Product adherence averaged 97.7%. Conclusions: CLB101 TM was safe and tolerable and significantly improved overall GI symptom burden, reflux, and abdominal pain after four weeks of daily supplementation in overweight symptomatic adults. Trial Registration: The trial was approved by Sterling IRB (14583-NACraft) and registered with ClinicalTrials.gov ( NCT07336615 ).
- Open Access
- 1 January 2026
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry B
- Vol. 14 (29) , 9035-9047
Drug Delivery with Fewer Fouls: Localized Antibiotic Release and Reduced Surface Biofouling with Glutathione-conjugated Hydrogels
Systemic antibiotics are the standard of care for acute bacterial skin and skin structure infections (ABSSSI), but low drug perfusion at the site of infection and higher rates of antibiotic...
- 1 January 2026
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry B
- Vol. 14 (29) , 9035-9047
Open AccessDrug Delivery with Fewer Fouls: Localized Antibiotic Release and Reduced Surface Biofouling with Glutathione-conjugated Hydrogels
Systemic antibiotics are the standard of care for acute bacterial skin and skin structure infections (ABSSSI), but low drug perfusion at the site of infection and higher rates of antibiotic...
- Open Access
- 17 August 2021
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 65 (9) , AAC0069221
Generating Genotype-Specific Aminoglycoside Combinations with Ceftazidime/Avibactam for KPC-Producing Klebsiella pneumoniae
Antibiotic combinations, including ceftazidime/avibactam (CAZ/AVI), are frequently employed to combat KPC-producing Klebsiella pneumoniae (KPC-Kp), though such combinations have not been rationally optimized. Clinical KPC-Kp isolates with common genes encoding aminoglycoside-modifying enzymes (AMEs), aac(6′)-Ib′ or aac(6′)-Ib , were used in static time-kill assays ( n = 4 isolates) and the hollow-fiber infection model (HFIM; n = 2 isolates) to evaluate the activity of gentamicin, amikacin, and CAZ/AVI alone and in combinations.
- 17 August 2021
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 65 (9) , AAC0069221
Open AccessGenerating Genotype-Specific Aminoglycoside Combinations with Ceftazidime/Avibactam for KPC-Producing Klebsiella pneumoniae
Antibiotic combinations, including ceftazidime/avibactam (CAZ/AVI), are frequently employed to combat KPC-producing Klebsiella pneumoniae (KPC-Kp), though such combinations have not been rationally optimized. Clinical KPC-Kp isolates with common genes encoding aminoglycoside-modifying enzymes (AMEs), aac(6′)-Ib′ or aac(6′)-Ib , were used in static time-kill assays ( n = 4 isolates) and the hollow-fiber infection model (HFIM; n = 2 isolates) to evaluate the activity of gentamicin, amikacin, and CAZ/AVI alone and in combinations.
- Open Access
- 11 June 2021
- Published by Springer Nature in Pharmaceutical Research
- Vol. 38 (7) , 1247-1261
Glutathione-Conjugated Hydrogels: Flexible Vehicles for Personalized Treatment of Bacterial Infections
Purpose Skin and soft tissue infections are increasingly prevalent and often complicated by potentially fatal therapeutic hurdles, such as poor drug perfusion and antibiotic resistance. Delivery vehicles capable of versatile loading may improve local bioavailability and minimize systemic toxicities yet such vehicles are not clinically available. Therefore, we aimed to expand upon the use of glutathione-conjugated poly(ethylene glycol) GSH-PEG hydrogels beyond protein delivery and evaluate the ability to deliver traditional therapeutic molecules. Methods PEG and GSH-PEG hydrogels were prepared using ultraviolet light (UV)-polymerization. Hydrogel loading and release of selected drug candidates was examined using UV-visible spectrometry. Therapeutic molecules and GST-fusion protein loading was examined using UV-visible and fluorescent spectrometry. Efficacy of released meropenem was assessed against meropenem-sensitive and -resistant P. aeruginosa in an agar diffusion bioassay. Results For all tested agents, GSH-PEG hydrogels demonstrated time-dependent loading whereas PEG hydrogels did not. GSH-PEG hydrogels released meropenem over 24 h. Co-loading of biologic and traditional therapeutics into a single vehicle was successfully demonstrated. Meropenem-loaded GSH-PEG hydrogels inhibited the growth of meropenem-sensitive and resistant P. aeruginosa isolates. Conclusion GSH ligands within GSH-PEG hydrogels allow loading and effective delivery of charged therapeutic agents, in addition to biologic therapeutics. Graphical abstract
- 11 June 2021
- Published by Springer Nature in Pharmaceutical Research
- Vol. 38 (7) , 1247-1261
Open AccessGlutathione-Conjugated Hydrogels: Flexible Vehicles for Personalized Treatment of Bacterial Infections
Purpose Skin and soft tissue infections are increasingly prevalent and often complicated by potentially fatal therapeutic hurdles, such as poor drug perfusion and antibiotic resistance. Delivery vehicles capable of versatile loading may improve local bioavailability and minimize systemic toxicities yet such vehicles are not clinically available. Therefore, we aimed to expand upon the use of glutathione-conjugated poly(ethylene glycol) GSH-PEG hydrogels beyond protein delivery and evaluate the ability to deliver traditional therapeutic molecules. Methods PEG and GSH-PEG hydrogels were prepared using ultraviolet light (UV)-polymerization. Hydrogel loading and release of selected drug candidates was examined using UV-visible spectrometry. Therapeutic molecules and GST-fusion protein loading was examined using UV-visible and fluorescent spectrometry. Efficacy of released meropenem was assessed against meropenem-sensitive and -resistant P. aeruginosa in an agar diffusion bioassay. Results For all tested agents, GSH-PEG hydrogels demonstrated time-dependent loading whereas PEG hydrogels did not. GSH-PEG hydrogels released meropenem over 24 h. Co-loading of biologic and traditional therapeutics into a single vehicle was successfully demonstrated. Meropenem-loaded GSH-PEG hydrogels inhibited the growth of meropenem-sensitive and resistant P. aeruginosa isolates. Conclusion GSH ligands within GSH-PEG hydrogels allow loading and effective delivery of charged therapeutic agents, in addition to biologic therapeutics. Graphical abstract